Halozyme Therapeutics (HALO) Falls Short of Q4 Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $130.06 -0.21%
Revenue Growth %: +37.6%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
KELYA, ROX, KEEL, More
Revenue Growth %: +37.6%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
KELYA, ROX, KEEL, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (Nasdaq: HALO) reported Q4 loss of $0.17, $0.05 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $3.6 million versus the consensus estimate of $5.33 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Halozyme Therapeutics (HALO) PT Raised to $79 at JPMorgan
- Gildan Activewear (GIL) Misses Q3 EPS by 3c ; Offers Guidance
- Loar Holdings Inc. (LOAR) Reports Q3 EPS of $0.39 ; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
